Gaudium IVF Sees Over Sevenfold Increase in Bids on Third Day of IPO, Driven by Strong Net Interest Income and Retail Demand.

Gaudium IVF & Women Health IPO Update

Key Highlights:

• ₹165 crore IPO closed on February 24 with a healthy response from investors, booking 7.27 times as against the offered 1.46 crore shares.
• Non-institutional investor (NII) category subscribed 14.05 times, while retail individual investor (RII) portion saw a 7.60 times subscription.
• Qualified institutional buyer (QIB) segment was booked 1.62 times.

Grey Market Premium:

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

• The grey market premium (GMP) for Gaudium IVF IPO has declined to ₹3, signaling a listing price of ₹82, a premium of 3.80% over the upper end of the price band of ₹79.

IPO Details:

• Gaudium IVF raised ₹49.5 crore from anchor investors ahead of the public issue.
• The ₹165-crore IPO is valued at around ₹575 crore, with a price band of ₹75–79 per share.
• Proceeds from the fresh issue will be used to establish 19 new IVF centres across India, repay debt, and meet general corporate expenses.

Financial Performance:

Read also: Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO

• Gaudium IVF reported revenue from operations of ₹70.72 crore and a profit after tax (PAT) of ₹19.13 crore for the financial year ended March 31, 2025.
• The company operates on a hub-and-spoke model, with seven hubs and 28 spokes across multiple states, and has positioned itself as a key player in assisted reproductive technologies in India.

Listing and Allotment:

• Investor focus will now shift to the allotment, which is slated to be finalised on February 25.
• The listing of Gaudium IVF shares will take place on BSE and NSE on February 27.